Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,670 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Tucson, ArizonaAges 18 years+ - NCT06066437RecruitingPhase 1/Phase 2
Lutetium before prostate surgery for high-risk cancer
This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Houston, TexasAges 18 years+ - NCT07278336RecruitingPhase 1
Study of ABBV901 for ovarian cancer
This trial tests a new drug called ABBV901, given alone or with another drug (bevacizumab), for people with a certain type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if it helps control the disease.
Denver, ColoradoAges 18 years+ - NCT03245411Recruiting
Helps cancer patients take oral medicines as prescribed
This study tests a set of practical support steps to help people with advanced cancer take their oral (by mouth) treatment medicines correctly. It may help improve adherence and reduce missed doses or appointments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT03310879RecruitingPhase 2
Abemaciclib for advanced tumors with cyclin or CDK4/6 gene changes
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
Boston, MassachusettsAges 18 years+ - NCT03408964Recruiting
Blood tests to predict treatment response in prostate cancer
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
BellinzonaAges 18 years+ - NCT03417115Recruiting
Breast cancer registry study of treatment and outcomes
This is a registry study that collects real-world information about breast cancer care at the start of treatment. It may help researchers better understand which treatments work best for different groups of people.
Many LocationsAges 18 years+ - NCT03671044RecruitingPhase 3
Testing a nano-form of docetaxel for triple-negative breast cancer
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
Columbus, GeorgiaAges 18–65 - NCT03694756Recruiting
Testing special MRI to see tiny breast cancer structures
This study is testing whether a special MRI scan can help show tiny features inside breast tumors (TMEM). It’s mainly a “feasibility” study, meaning the team is checking if the scan can be done safely and clearly in different types of operable breast cancer.
The Bronx, New YorkAges 18 years+ - NCT03788213Recruiting
Shorter vs longer radiation after breast cancer surgery
This trial compares giving breast radiation over one week versus three weeks after surgery. It aims to see whether the shorter schedule works just as well and is safe for people with certain types of early breast cancer.
Kolkata, West BengalAges 18 years+ - NCT03841617RecruitingPhase 2
Measure radiation in thyroid cancer using a special PET-CT scan
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
Bethesda, MarylandAges 18–90 - NCT03888950Recruiting
Interim PET-CT scan to assess anti-PD-1 treatment in melanoma
This study checks an “interim” whole-body scan (PET-CT) partway through treatment to see how well anti-PD-1 immunotherapy (nivolumab or pembrolizumab) is working for advanced melanoma. It may help doctors better understand early treatment response and guide next steps.
Nice, CHU de NICEAges 18 years+ - NCT03926338RecruitingPhase 2
Before-surgery immunotherapy for MSI-H or dMMR colon cancer
This trial studies a treatment given before surgery using toripalimab, with or without celecoxib, for colon or rectal cancer that has MSI-H or dMMR tumor features. It aims to shrink or control the cancer before the operation and compare whether adding celecoxib helps.
Guangzhou, GuangdongAges 18–75 - NCT03929549Recruiting
Testing a tool to predict jaw surgery failure for sleep apnea
This trial studies a way to predict which people with obstructive sleep apnea (OSA) may not do well after maxillomandibular advancement surgery (jaw advancement). It could help doctors choose the right treatment and avoid ineffective surgery.
Ann Arbor, MichiganAges 30–65 - NCT03971045RecruitingPhase 2
Pembrolizumab plus low-dose oral chemo for chest wall breast cancer
This Phase 2 trial tests pembrolizumab (an immune therapy) plus low-dose oral cyclophosphamide in people with chest wall breast cancer that has spread locally and may have distant metastases. It aims to see if this combination can shrink tumors and control cancer longer, especially in tumors with certain immune markers.
MilanAges 18 years+ - NCT03847649RecruitingPhase 2
Durvalumab for cancer after stopping immune therapy due to side effects
This Phase 2 trial tests whether durvalumab (an immunotherapy) can still help treat advanced cancer after you had to stop an earlier immune checkpoint medicine because of immune-related side effects. If you’re already on a durvalumab-based study, Substudy B also looks at continuing durvalumab (with or without tremelimumab) when it’s safe for you.
Edmonton, AlbertaAges 18 years+ - NCT05533697RecruitingPhase 1/Phase 2
mRNA medicine with or without immunotherapy for advanced solid cancers
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Los Angeles, CaliforniaAges 12 years+ - NCT04063527RecruitingPhase 3
Stage I ovarian cancer treatment after surgery
This trial studies whether an additional treatment after surgery can help people with early-stage epithelial ovarian cancer live longer and stay well for more time. It is meant for patients who had a detailed staging operation and are able to start treatment within 8 weeks.
Nagakute-shi, Aichi-kenAges 20 years+ - NCT04092660Recruiting
Mouth guard study to reduce airway collapse in sleep apnea
This study tests whether using an anti-snoring mouth guard (a mandibular advancement appliance) can help keep your airway open during sleep if you have obstructive sleep apnea. If you’re referred for this kind of mouth guard, the trial will see if using it more regularly or in a specific way improves symptoms or breathing during sleep.
LondonAges 40–90 - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Los Angeles, CaliforniaAges 18 years+ - NCT04204850RecruitingPhase 2
Cabozantinib for liver cancer that returns after liver transplant
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
Toronto, OntarioAges 18 years+ - NCT04215003RecruitingPhase 1/Phase 2
Study breast cancer treatment guided by tumor pathway tests
This trial tests new treatment given before surgery for certain stage IIb–IIIc breast cancers. It uses results from your tumor to guide the treatment plan and aims to improve how well the therapy works before the operation.
Shanghai, Please SelectAges 18–70 - NCT04235764Recruiting
Testing a new bladder-tumor surgery tool for removed tissue
This trial studies a redesigned surgical instrument used during bladder tumor removal, to see if it can improve how the removed tissue samples are collected. It may help future patients by supporting better study of bladder tissue during cancer care.
Bethesda, MarylandAges 18–120
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,670 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.